Scholarlink

Introduction <p>Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease frequently associated with other immune-mediated inflammatory diseases (IMIDs), such as systemic lupus erythematosus (SLE) and psoriasis. Although advanced therapies have improved HS outcomes, many patients continue to experience suboptimal control, particularly when managing concurrent comorbidities. Combination therapy with biologics and small molecules may offer an effective strategy in select complex cases.</p> Methods <p>We present three female patients with moderate-to-severe HS and systemic comorbidities (two with paradoxical palmoplantar psoriasis, one with SLE) who were treated with a combination of secukinumab and upadacitinib. All had previously failed at least two conventional systemic therapies. Secukinumab 300&#xa0;mg was initiated first, followed by the addition of upadacitinib (15–30&#xa0;mg) after 5–6&#xa0;months.</p> Results <p>The combination achieved significant improvement in HS activity and complete or near-complete resolution of comorbid conditions. Treatment was well tolerated, with no discontinuations or adverse events reported over 3–6&#xa0;months of follow-up.</p> Conclusion <p>Our findings suggest that dual targeted therapy may represent a viable approach for patients with refractory disease and multiple immune-mediated conditions, warranting further investigation in larger cohorts.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Secukinumab Plus Upadacitinib for the Treatment of Severe Hidradenitis Suppurativa and Associated Immune-Mediated Comorbidities: A Case Series

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月16日

查看全文
  • Francisco Javier Melgosa Ramos,
  • Esperanza Martínez Ruiz,
  • Marta Galarreta Pascual,
  • Virginia Sanz-Motilva,
  • Antonio Martorell

摘要

Introduction

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease frequently associated with other immune-mediated inflammatory diseases (IMIDs), such as systemic lupus erythematosus (SLE) and psoriasis. Although advanced therapies have improved HS outcomes, many patients continue to experience suboptimal control, particularly when managing concurrent comorbidities. Combination therapy with biologics and small molecules may offer an effective strategy in select complex cases.

Methods

We present three female patients with moderate-to-severe HS and systemic comorbidities (two with paradoxical palmoplantar psoriasis, one with SLE) who were treated with a combination of secukinumab and upadacitinib. All had previously failed at least two conventional systemic therapies. Secukinumab 300 mg was initiated first, followed by the addition of upadacitinib (15–30 mg) after 5–6 months.

Results

The combination achieved significant improvement in HS activity and complete or near-complete resolution of comorbid conditions. Treatment was well tolerated, with no discontinuations or adverse events reported over 3–6 months of follow-up.

Conclusion

Our findings suggest that dual targeted therapy may represent a viable approach for patients with refractory disease and multiple immune-mediated conditions, warranting further investigation in larger cohorts.